ArticleMolecular and cellular biochemistry2006
(-)Schisandrin B is more potent than its enantiomer in enhancing cellular glutathione and heat shock protein production as well as protecting against oxidant injury in H9c2 cardiomyocytes.
Article in Molecular and cellular biochemistry, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 21 citations in OpenAlex.
- Schizandrin B inhibits the cis‑DDP‑induced apoptosis of HK‑2 cells by activating ERK/NF‑κB signaling to regulate the expression of survivin.International journal of molecular medicine · 2018Article
- Extraction and Separation of Active Ingredients in Schisandra chinensis (Turcz.) Baill and the Study of their Antifungal Effects.PloS one · 2016Article
- Schisandrin B elicits a glutathione antioxidant response and protects against apoptosis via the redox-sensitive ERK/Nrf2 pathway in H9c2 cells.Molecular and cellular biochemistry · 2011Article
- Effects of Adaptogens on the Central Nervous System and the Molecular Mechanisms Associated with Their Stress-Protective Activity.Pharmaceuticals (Basel, Switzerland) · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effects of schisandrin B enantiomers ((+)Sch B and (-)Sch B) treatment on cellular reduced glutathione (GSH) level and heat shock protein (Hsp)25/70 production were investigated in H9c2 cardiomyocytes. (+)Sch B and (-)Sch B at 6.25 muM produced a time-dependent and biphasic change in cellular GSH level and Hsp25/70 production, with the stimulatory effect of (-)Sch B being more potent. The GSH- and Hsp-enhancing effects were accompanied by a parallel cytoprotection against xanthine oxidase/xanthine-induced toxicity, with the biphasic time course of (+)Sch B- or (-)Sch B-induced protection being superimposed with that of the increase in GSH level but not Hsp25/70 production. The results indicate that (-)Sch B produces more potent enhancing effects on cellular GSH and Hsp production as well as protection against oxidative injury than (+)Sch B in cardiomyocytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.